331 related articles for article (PubMed ID: 20951424)
1. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Forestier N; Larrey D; Marcellin P; Guyader D; Patat A; Rouzier R; Smith PF; Qin X; Lim S; Bradford W; Porter S; Seiwert SD; Zeuzem S
J Infect Dis; 2011 Aug; 204(4):601-8. PubMed ID: 21791662
[TBL] [Abstract][Full Text] [Related]
4. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
9. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
10. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
11. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW; Kulkarni R; Gane EJ; Roberts SK; Stedman C; Angus PW; Ritchie B; Lu XY; Ipe D; Lopatin U; Germer S; Iglesias VA; Elston R; Smith PF; Shulman NS
Gastroenterology; 2012 Apr; 142(4):790-5. PubMed ID: 22248659
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Pol S; Ghalib RH; Rustgi VK; Martorell C; Everson GT; Tatum HA; Hézode C; Lim JK; Bronowicki JP; Abrams GA; Bräu N; Morris DW; Thuluvath PJ; Reindollar RW; Yin PD; Diva U; Hindes R; McPhee F; Hernandez D; Wind-Rotolo M; Hughes EA; Schnittman S
Lancet Infect Dis; 2012 Sep; 12(9):671-7. PubMed ID: 22714001
[TBL] [Abstract][Full Text] [Related]
14. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
[TBL] [Abstract][Full Text] [Related]
16. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
20. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Jensen DM; Brunda M; Elston R; Gane EJ; George J; Glavini K; Hammond JM; Le Pogam S; Nájera I; Passe S; Piekarska A; Rodriguez I; Zeuzem S; Chu T;
Liver Int; 2016 Apr; 36(4):505-14. PubMed ID: 26519669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
